[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hamilton Health Sciences Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":677},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,45,73,101,136,166,188,213,236,261,283,305,331,355,383,408,433,458,478,508,542,567,592,614,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645140","prevention-of-vascular-graft-infection-with-hypochlorous-acid-100645140",false,"NCT07678632","Prevention of Vascular Graft Infection With Hypochlorous Acid","Prevention of Vascular Graft Infection With Hypochlorous Acid - A Pilot Study","Inclusion Criteria:\n\n* Patients undergoing elective or emergent open insertion of prosthetic vascular grafts to the abdominal and\u002For lower limb vessels, including all prosthetic bypass grafts and patch grafts\n* Patients 18 years of age or older\n* Able to provide informed consent in English\n\nExclusion Criteria:\n\n* Patients undergoing vascular surgery that does not involve the insertion of a prosthetic graft to the abdominal and\u002For lower limb vessels by an open operation\n* Patients under the age of 18 years\n* Patients who are unable to provide informed consent in English","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a study of the use of an antibacterial solution, Hypochlorous acid, to prevent infection in vascular surgery bypass grafts. The solution will be used at the end of operations to insert a prosthetic vascular surgery bypass graft, to wash the wound and the vascular bypass graft before the wound is closed. The patients in this study will be undergoing surgery for problems with narrowed and or blocked arteries. The presence or absence of a graft infection will be followed for 12 months following the surgery. Prosthetic vascular graft infections have significant implications for patients with high rates of death and amputation, hence preventing them will have significant benefits for patients and the health care system.",[27],"Vascular Prosthetic Graft Infection",[27,29,30,31],"Infection Prevention","Hypochlorous acid","Wound lavage","NOT_YET_RECRUITING","2026-06-24",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":21},"2026-08-03",{"date":40,"type":21},"2028-08-03",{"name":42,"class":43},"Hamilton Health Sciences Corporation","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100591350","intravascular-ultrasound-for-peripheral-artery-disease-revascularization-100591350","NCT06979284","Intravascular Ultrasound for Peripheral Artery Disease Revascularization","Intravascular Ultrasound for Peripheral Artery Disease Revascularization: The CLARITY Randomized Controlled Trial","CLARITY","Inclusion Criteria:\n\n1. Patients presenting with lower extremity PAD manifesting as CLTI:\n\n   a. CLTI is defined as ischemic rest foot pain, nonhealing wounds, or gangrene present for at least two weeks and that is attributable to objectively proven arterial occlusive disease, compatible with Rutherford class 4, 5 or 6, with the following supporting hemodynamic criteria1: i. For ischemic rest pain (Rutherford category 4): Ankle systolic pressure \\\u003C 40mmHg, toe pressure \\\u003C 30mmHg, or flat-line transtarsal pulse volume recording, OR ii. For tissue loss (Rutherford category 5, 6): Ankle systolic pressure \\\u003C 60 mmHg, toe pressure of \\\u003C 40mmHg, or flat-line transtarsal volume recording, AND\n2. Scheduled to undergo percutaneous revascularization, AND\n3. Informed consent\n4. Imaging evidence of an obstructive or occluded lesion (\\> 70%) in the infraiguinal circulation (e.g. femoral, popliteal, or infrapopliteal circulation) using angiography, ultrasound, computed tomography, or magnetic resonance imaging.\n5. An infrapopliteal lesion must be located in the proximal 2\u002F3 of native infrapopliteal vessels, with a vessel diameter of \\> 2.5mm by investigator visual assessment.\n6. The distal margin of the most distal target lesion must be located \\> 10 cm proximal to the proximal margin on the ankle mortise. The vessel segment distal to the most distal target lesion must be patent all the way to the ankle, with no obstructive lesion (\\>50% stenosis).\n\nExclusion Criteria:\n\n1. The presence of anatomic or comorbid conditions or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the potential participant's ability to participate in the trial or to comply with the follow-up requirements.\n2. The presence of any medical conditions precluding percutaneous revascularization\n3. The subject has previously had or requires surgical revascularization involving the vessel containing the target lesion of the ipsilateral extremity.\n4. The subject is bedridden or unable to walk (with assistance is acceptable).\n5. Life expectancy \\\u003C 12 months\n6. Age \\\u003C 18 years\n7. Active vasculitis, Buerger's disease, or acute limb-threatening ischemia\n8. Planned above-ankle amputation of the index limb within four weeks of the index procedure.\n9. Obstructive supra-inguinal \"inflow\" (\\>70% stenosis) which is not planned to be treated during index procedure or within 30 days of the index procedure.\n10. The subject has had any amputation to the ipsilateral extremity other than the toe or forefoot, or the subject has had a major amputation to the contralateral extremity \\\u003C 1 year before the index procedure and is not independently walking.\n11. Extensive tissue loss that is salvageable only with complex foot reconstruction or non-traditional trans metatarsal amputations.\n\n    1. Osteomyelitis that extends proximal to the metatarsal heads\n    2. Gangrene involving the plantar skin of the forefoot, midfoot or heel\n    3. Deep ulcer or large shallow ulcer (\\> 3 cm) involving the plantar skin of the f forefoot, midfoot, or heel\n    4. Full-thickness heel ulcer\n    5. Any wound with calcaneal bone involvement\n    6. Wounds that would require flap coverage or complex wound management for large soft tissue defect\n    7. Full-thickness wounds on the dorsum of the foot with exposed tendon or bone.",{"count":54,"type":21},772,[24],"The purpose of this study is to determine if IVUS use, as compared to angiography alone, prevent major adverse limb events (MALE) or binary restenosis (a greater than 50% re-narrowing of the treated artery) in adult patients who have CLTI and are undergoing percutaneous revascularization.",[58,59,60,61,62],"Peripheral Arterial Disease(PAD)","Chronic Limb Threatening Ischemia","Intravascular Ultrasound","Major Adverse Limb Events","Restenosis","RECRUITING","2026-06-04",{"date":66,"type":36},"2026-06-08",{"date":68,"type":36},"2025-12-05",{"date":70,"type":21},"2030-10",{"name":42,"class":43},2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100513302","the-fourth-left-atrial-appendage-occlusion-study-100513302","NCT05963698","The Fourth Left Atrial Appendage Occlusion Study","The Fourth Left Atrial Appendage Occlusion Study (LAAOS-4)","LAAOS-4","Inclusion Criteria:\n\n1. (a) Persistent or permanent atrial fibrillation OR (b) Paroxysmal atrial fibrillation in participants with a history of ischemic stroke or systemic embolism\n2. Increased risk of stroke, defined as a CHA2DS2-VASc stroke risk score of ≥ 4. \\[Note: the acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female).\\]\n3. Treatment with oral anticoagulants (Vitamin K agonist or factor Xa inhibitor) for at least 90 days prior to enrollment, AND no documented plan to discontinue treatment with oral anticoagulants for the expected duration of the trial.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Current left atrial appendage thrombus\n3. Prior left atrial appendage occlusion or removal (surgical or percutaneous)\n4. Prior percutaneous atrial septal defect or patent foramen ovale closure\n5. Prior atrial fibrillation ablation unless evidence of recurrent qualifying atrial fibrillation present at least 30 days following ablation\n6. Planned atrial fibrillation ablation within 90 days of enrollment\n7. Individuals being treated with direct thrombin inhibitors\n8. Women of childbearing potential unless they agree to employ effective birth control methods throughout the study\n9. Anticipated life-expectancy of \\\u003C 2 years\n10. Patient unable or willing to give informed consent",{"count":82,"type":21},4000,[24],"LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.",[86,87,88],"Atrial Fibrillation","Stroke, Ischemic","Systemic Embolism",[90,91,92,93],"WATCHMAN","Left Atrial Appendage (LAA)","LAA Device","Left Atrial Appendage Occlusion",{"date":66,"type":36},{"date":96,"type":36},"2023-11-30",{"date":98,"type":21},"2029-12-01",{"name":42,"class":43},140,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100561684","fecal-microbiota-transplant-for-anorexia-nervosa-100561684","NCT06593366","Fecal Microbiota Transplant for Anorexia Nervosa","A Pilot Feasibility Randomized Controlled Trial of Fecal Microbiota Transplant for Adolescent Anorexia Nervosa","FMT-AN","Inclusion Criteria: All study subjects will have been diagnosed with AN (restricting type or binge eating\u002Fpurging type) by the primary physician on the ED team, as per standard approach. Study participants will:\n\n* Be 12-17 years-old at time of recruitment\n* Have capacity to consent\n* Be assigned female sex at birth (may be gender diverse)\n* Be active patients in the pediatric ED program at MCH\n* Have a weight that is \\\u003C85% of the Treatment Goal Weight, as determined by the treating physician\n\nExclusion Criteria: Potential study subjects will be excluded due to the following reasons:\n\n* Exposure to antibiotics within two weeks of study randomization\n* Initiation of new probiotics \u002F oral nutritional supplements within two weeks of randomization\n* Active pregnancy\n* Active psychosis or suicidal ideation\n* Other comorbidities that may affect weight or the gut microbiome including celiac disease, inflammatory bowel disease (or other conditions as determined by the study team)","FEMALE","12 Years","17 Years",{"count":113,"type":21},20,[24],"The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary effectiveness among patients with anorexia nervosa (AN). Specifically, the investigators aim to compare changes in weight, gut microbiome, urine, blood biomarkers and mood symptoms between participants receiving the FMT intervention and placebo.",[117,118,119,120,121],"Anorexia Nervosa Restricting Type","Anorexia Nervosa","Anorexia in Adolescence","Anorexia in Children","Anorexia",[123,124,125,126,127],"anorexia nervosa","fecal microbiota transplant","pilot study","randomized controlled trial","feasibility","2026-05-22",{"date":130,"type":36},"2026-05-27",{"date":132,"type":21},"2026-06-01",{"date":134,"type":21},"2027-06-01",{"name":42,"class":43},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":148,"conditions":149,"keywords":154,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100542051","phase-3-bleeding-reduction-in-acute-and-chronic-kidney-patients-having-surgery-brackets-pilot-trial-100542051","NCT06337838","Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial","BRACKETS","Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:\n\n1. One of either:\n\n   1.1. eGFR \\\u003C25 ml\u002Fmin\u002F1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;\n2. Planned noncardiac surgery (elective, urgent, or emergency surgery);\n3. Expected to require at least an overnight hospital admission after surgery;\n4. Age ≥18 years; and\n5. Informed consent is obtained to participate in the BRACKETS-Pilot Trial.\n\nExclusion Criteria:\n\n1. Undergoing cardiac surgery;\n2. Undergoing intracranial neurosurgery;\n3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;\n4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;\n5. Hypersensitivity or known allergy to TXA;\n6. History of seizure disorder;\n7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;\n8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;\n9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or\n10. Previously enrolled in the BRACKETS-Pilot Trial.\n\nEligibility criteria specific to the desmopressin factorial component of trial\n\nInclusion criteria:\n\n1\\. Included in the TXA factorial.\n\nExclusion criteria:\n\n1. The hospital does not have access to desmopressin;\n2. Planned use of prophylactic desmopressin;\n3. Most recent serum sodium concentration \\\u003C 130 mEq\u002FL;\n4. Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or\n5. Hypersensitivity or known allergy to desmopressin.",{"count":145,"type":21},100,[147],"PHASE3","The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.",[150,151,152,153],"Chronic Kidney Diseases","Acute Kidney Injury","Bleeding","Surgery",[155,156,157],"Major Noncardiac Surgery","Tranexamic Acid","Desmopressin","2026-05-20",{"date":128,"type":36},{"date":161,"type":36},"2025-06-09",{"date":163,"type":21},"2027-06",{"name":42,"class":43},3,{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":44},"100525813","phase-3-infection-prophylaxis-in-total-joint-replacement-100525813","NCT06126614","Infection Prophylaxis in Total Joint Replacement","Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement (PREVENT-iT)","PREVENT-iT","Inclusion Criteria:\n\n1. Patients 18 years of age or older.\n2. Undergoing primary or aseptic revision TJR.\n3. No contraindications to study interventions.\n4. Informed consent (participant or substitute decision maker) obtained and willing to comply with the protocol.\n\nExclusion Criteria:\n\n1. Received antibiotics for any reason in the two weeks prior to their TJR.\n2. Chronic or acute infection at or near the TJR site.\n3. Prior history of periprosthetic joint infection including any reoperation due to infection.\n4. Undergoing surgery for a diagnosis of a fracture.\n5. Open infected wounds on affected limb.\n6. Undergoing bilateral TJR.\n7. Currently enrolled in a study that does not permit co-enrollment.\n8. Prior enrollment in the trial including the pilot study\n9. Any condition or circumstance, which in the opinion of the Investigator, interferes with assessments or completion of the trial.",{"count":175,"type":21},21006,[147],"Osteoarthritis (OA) is the most common cause of disability in older adults worldwide affecting 7% of the global population, or more than 500 million people globally. Total joint replacements (TJR) can help bring relief to those with osteoarthritis when other treatment options are no longer helpful. Infection is the main reason hip and knee replacements \"fail\". Failure leads to repeat surgeries that are often more complicated and less likely to be successful than the first surgery. Reducing the risk of infection is extremely important, antiseptic washes and antibiotics may help us do that. After joint replacement surgery, orthopaedic surgeons wash and clean the surgical wound to lower the risk of infection. The goal of this clinical trial is to determine if the use of antiseptic solutions to wash the surgical site and placing an antibiotic directly into the wound will reduce the number of infections requiring reoperation. Patients having total joint replacements will be randomized (like flipping a coin) to receive 6 possible combinations of washes and \u002F or antibiotics. Participants will be followed for one year after TJR to compare the rate of infection in each group.",[179],"Periprosthetic Joint Infection",[181],"Arthroplasty",{"date":128,"type":36},{"date":184,"type":36},"2024-05-07",{"date":186,"type":21},"2028-11",{"name":42,"class":43},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100633990","acss-approach-on-dysphagia-100633990","NCT07533864","ACSS Approach on Dysphagia","Anterior Cervical Spine Strap Muscle Splitting Versus Smith-Robinson Approach: A Single-Centre Observational Study","Inclusion Criteria:\n\n* Adult patients (18 years of age or older).\n* Patients undergoing anterior cervical spine surgery including Anterior cervical discectomy and fusion (ACDF), Anterior cervical arthroplasty (ACA) and Anterior cervical corpectomy and fusion (ACCF)\n* Ability to complete HSS-DDI questionnaire in English\n\nExclusion Criteria:\n\n* Planned use of anterior odontoid screws\n* Revision anterior surgery\n* Trauma patient",{"count":145,"type":21},"OBSERVATIONAL","Anterior cervical spine surgery (ACSS) is a procedure for the treatment of several neck problems. Even though the procedure is overall safe and effective, there are possible complications after surgery, which include problems swallowing, hoarseness of the voice, and pain when swallowing.\n\nThere are two different ways the spinal surgeon can approach the spine from the front of the neck. One is called a Smith-Robinson approach, and the other is called a strap-splitting approach. Each approach uses the same skin cut, the difference is only in how the next layer is approached, whether on the outside (Smith-Robinson) or through (strap-splitting) one of the small muscles in your neck. Because of the slightly different approaches to the surgery, we want to see if there are differences in complications related to swallowing and speaking between these two approaches.\n\nParticipants will undergo one of the two surgical approaches, based on surgeon preference. Participants will complete a questionnaire at several time points during their clinical follow-up to assess any difficulties swallowing and speaking.",[199],"Anterior Cervical Spine Surgery",[201,202,203,204],"anterior cervical spine surgery","dysphagia","Smith-Robinson","strap-splitting","2026-04-24",{"date":207,"type":36},"2026-04-29",{"date":209,"type":21},"2026-04",{"date":211,"type":21},"2029-07",{"name":42,"class":43},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100634997","ai-enhanced-wide-field-endoscopic-fluorescence-mapping-of-gastrointestinal-mucosal-permeability-in-ibd---a-pilot-study-in-ibd-patients-and-controls-100634997","NCT07546955","AI-Enhanced Wide-Field Endoscopic Fluorescence Mapping of Gastrointestinal Mucosal Permeability in IBD - A Pilot Study in IBD Patients and Controls","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Able to provide written informed consent\n* Established ulcerative colitis or Crohn's disease involving the colon, or non-IBD control undergoing screening\u002Fsurveillance colonoscopy\n* Undergoing clinically indicated colonoscopy\n* Ability to comply with study procedures\n\nExclusion Criteria:\n\n* Allergy to fluorescein\n* Colorectal cancer\n* Advanced polyps or malignant lesions identified during colonoscopy\n* Significant cardiopulmonary disease\n* Renal failure\n* Active infection or sepsis\n* Severe IBD flare\n* Use of medications that may affect gut permeability, including NSAIDs or antibiotics\n* Inability to tolerate bowel preparation or safely complete the protocol\n* Pregnancy or breastfeeding\n* Inability or unwillingness to provide informed consent or comply with study procedures",{"count":220,"type":21},70,"This pilot study will test a new imaging system that uses fluorescent dye and artificial intelligence (AI) during colonoscopy to measure how \"leaky\" the lining of the colon is in people with inflammatory bowel disease (IBD). The study will include 70 adults at 3 Canadian hospitals: 60 people with ulcerative colitis or Crohn's disease affecting the colon, and 10 people without IBD who are having colonoscopy for routine colorectal cancer screening or surveillance. During the colonoscopy, participants will receive intravenous fluorescein, and the imaging system will record fluorescence in the colon as the scope is withdrawn. The main goal is to find out whether this method can be used safely during routine colonoscopy and whether it can produce usable measurements of mucosal permeability. The study will also examine whether these measurements are related to standard measures of inflammation seen during endoscopy, in biopsy samples, and in ex vivo Ussing chamber testing at the McMaster site. The control group will help define what normal fluorescence and permeability look like. This study is intended to provide early data on whether this approach could become a useful new way to assess barrier dysfunction in IBD.",[223,224],"Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)","NON-IBD",[226,227],"IBD, CD, UC","Non-IBD","2026-04-17",{"date":230,"type":36},"2026-04-23",{"date":232,"type":21},"2026-04-01",{"date":234,"type":21},"2027-02-01",{"name":42,"class":43},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":165},"100616051","vascular-events-in-noncardiac-surgery-patients-cohort-evaluation-study-2-100616051","NCT07300579","Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study 2","VISION-2","Inclusion Criteria:\n\n1. age ≥65 years;\n2. underwent non-cardiac surgery with general, neuraxial, local, or regional anesthesia; and\n3. expected length of hospital stay of 3 or more days\n\nExclusion Criteria:\n\n1. hearing aid(s) or cochlear implant(s) in left ear;\n2. pacemaker\u002Fimplantable cardioverter-defibrillator (ICD);\n3. externally programmable cerebrospinal fluid shunt;\n4. deep brain stimulator;\n5. intolerance\u002Fallergy to adhesive;\n6. history of dementia, or;\n7. previous enrollment in the VISION-2 Study","65 Years",{"count":245,"type":21},20000,"VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Following study enrollment and baseline data collection, follow up visits will occur in-hospital, at 30-days, and 1-year post-operatively.\n\nVISION-2 has 3 primary objectives, among participants who underwent noncardiac surgery, the investigators will: 1) determine the pattern and frequency of physiological precursors (i.e., biophysical signals) to MINS, BIMS, sepsis, and infection without sepsis; 2) build prediction models from these biophysical signals and their extracted features through supervised machine learning, for the prediction and early detection of those complications; and 3) build a biobank for evaluation of novel biomarkers.",[248,249,250,251,252],"Myocardial Injury After Noncardiac Surgery (MINS)","Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS)","Sepsis","Infection Without Sepsis","Post-operative Complications","2026-04-09",{"date":255,"type":36},"2026-04-14",{"date":257,"type":21},"2026-06",{"date":259,"type":21},"2032-06",{"name":42,"class":43},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":269,"sex":109,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":44},"100519097","indocyanine-green-for-detection-of-sentinel-lymph-nodes-in-comparison-to-icg-plus-technetium-in-the-evaluation-of-vulvar-squamous-cell-carcinoma-100519097","NCT06039111","Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma","Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma: The IGNITE-V Study","IGNITE-V","Inclusion Criteria:\n\nAdult women (18 years of age) with FIGO Stage IB (\\> 1 mm depth of invasion) and small Stage II (4 cm) vulvar squamous cell carcinoma or cutaneous melanoma who are candidates for the Sentinel lymph node technique will be included (Negative clinical groin examination and\u002For imaging and primary unifocal vulvar tumor size of \\\u003C 4 cm).\n\nExclusion Criteria:\n\nWomen with a prior history of pelvic, vulvovaginal or inguinal radiation, with allergy or hypersensitivity to Technetium or ICG, or Bartholin gland cancer will be excluded.",true,{"count":271,"type":21},58,"The aim of this study is to confirm prospectively if the use of near infrared-indocyanine green (NIR-ICG) alone offers similar accuracy and sensitivity to the gold standard dual technique for sentinel lymph node detection in early stage vulvar cancer.",[274],"Vulvar Cancer","2026-04-08",{"date":277,"type":36},"2026-04-13",{"date":279,"type":36},"2023-10-01",{"date":281,"type":21},"2026-11-30",{"name":42,"class":43},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100559720","phase-4-prevention-of-infections-in-cardiac-surgery-pics-a-cluster-randomized-factorial-cross-over-trial-100559720","NCT06567808","Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial","PICS","Inclusion Criteria:\n\nAdult patients (≥18 years of age) undergoing open-heart surgery (i.e. sternotomy, including minimally-invasive surgical techniques through mini-sternotomies)\n\nExclusion Criteria:\n\n1. On systemic antibiotics or with an active bacterial infection at the time of surgery\n2. Previously enrolled in this trial\n3. Known to be colonized with methicillin-resistant staphylococcus aureus (MRSA). Where it is unethical to not administer glycopeptides.\n4. Beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively\n5. Participation in other studies that may interfere with this trial.\n6. Patients undergoing cardiac transplant",{"count":291,"type":21},38000,[293],"PHASE4","The goal of this pragmatic, multi-centre factorial cluster randomized cross-over trial is to assess the efficacy of a combination of cefazolin plus vancomycin compared to cefazolin monotherapy, as well as a comparison of short versus long-term prophylaxis with four study arms: 1) cefazolin short-term, 2) cefazolin long-term, 3) cefazolin plus vancomycin short-term and 4) cefazolin plus vancomycin long-term.",[296],"Infection, Surgical Site","2026-03-10",{"date":299,"type":36},"2026-03-12",{"date":301,"type":21},"2026-03-01",{"date":303,"type":21},"2028-07-30",{"name":42,"class":43},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":44},"100543258","phase-4-postop-pain-management-in-pituitary-tumour-patients-100543258","NCT06353529","Postop Pain Management in Pituitary Tumour Patients","Effect of Sphenopalatine Ganglion Block With Bupivacaine on Postoperative Pain in Patients Undergoing Endoscopic Pituitary Adenoma Resection","POPPY","Inclusion Criteria:\n\n* adult patients (18 yrs or older)\n* undergoing endonasal pituitary adenoma resection\n\nExclusion Criteria:\n\n* Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs\n* contraindications to the performance of SPGB such as known allergy to used medications\n* chronic alcohol abuse\n* uncontrolled systemic arterial hypertension\n* severe kidney or liver diseases\n* cardiomyopathies or sustained cardiac arrhythmias (permanent paroxystic atrial fibrillation or other sustained supraventricular rhythmic anomalies)","100 Years",{"count":315,"type":21},108,[293],"To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.",[319,320],"Pituitary","Pain, Postoperative",[322,323,324],"Nerve block","Bupivacaine","Sphenopalatine Ganglion",{"date":299,"type":36},{"date":327,"type":36},"2024-11-25",{"date":329,"type":21},"2026-07",{"name":42,"class":43},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":354},"100529472","phase-2-targeted-therapy-with-glycogen-synthase-kinase-3-inhibition-for-arrhythmogenic-cardiomyopathy-100529472","NCT06174220","Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy","TaRGET","Inclusion Criteria:\n\n* A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP\\*) rare variant OR the TMEM43-p.S358L variant\n\n  \\*JUP carriers must be homozygous or compound heterozygous\n* Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor\n* Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening\n\nExclusion Criteria:\n\n* NYHA class IV heart failure\n* Ventricular scar secondary to coronary artery disease\n* Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening\n* Any potentially harmful chronic liver disease\n* ALT value \\> 2X the upper limit of the normal reference range at Screening\n* Total bilirubin value greater than the upper limit of the normal reference range at Screening, unless documented Gilbert's syndrome. For individuals with Gilbert's syndrome, total bilirubin value greater than 2-fold the upper limit of the normal reference range at Screening.\n* A history of alcohol or illicit substance use disorders\n* Regular and long-term use of strong CYP3A4 inhibitors, including clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir\n* Serum creatinine \\> 150 micromole\u002FL or creatinine clearance ≤ 60 mL\u002Fmin (according to Cockcroft-Gault formula) at Screening\n* Pregnant at time of enrollment and women of childbearing age who do not use a highly effective form of contraception\n* Males, engaged in sexual relations with a female of child-bearing potential, not using an acceptable contraceptive method if not surgically sterile\n* Patients unwilling to provide informed consent or comply with follow-up\n* Hypersensitivity to tideglusib or any components of its formulation, including allergy to strawberry\n* Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window e.g. warfarin and digoxin",{"count":339,"type":21},120,[341],"PHASE2","The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.",[344,345],"Arrhythmogenic Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy",[347],"sudden cardiac death, ventricular cardiomyopathy, genetics, arrhythmia",{"date":299,"type":36},{"date":350,"type":36},"2025-03-21",{"date":352,"type":21},"2027-07-01",{"name":42,"class":43},17,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":44},"100603952","phase-2-precision-dosing-of-oral-ibuprofen-for-pda-a-pilot-rct-100603952","NCT07143201","Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT","Model Informed Precision Dosing of Oral Ibuprofen for Treatment of Persistent Patent Ductus Arteriosus: A Pilot Randomized Controlled Feasibility Trial","MIPD-PDA","Inclusion Criteria:\n\n* Neonates with a gestational age of ≤27+6 weeks\n* Admitted to the neonatal intensive care unit (NICU) at McMaster Children's Hospital (MCH)\n* Diagnosed with PDA in need of treatment based on targeted neonatal echocardiography (TnEcho) performed prior to 27+6 CGA or postnatal age of 3 days, whichever comes later.\n* Obtained parental consent.\n\nExclusion Criteria:\n\n* Major congenital or genetic abnormalities\n* Evidence for clinical or biochemical hepatic or renal failure (AST \\> 225 U\u002FL, ALT \\> 150 U\u002FL, or serum creatinine \\> 130 µmol\u002FL)\n* Sepsis - as defined by confirmed uncontrolled\u002Factive sepsis which will preclude any treatment of PDA\n* Contraindications to receive oral ibuprofen:\n* Severe hyperbilirubinemia in need for exchange transfusion\n* Severe feeding intolerance\n* Necrotizing enterocolitis (NEC)\n* Gastrointestinal perforation\n* Active bleeding\n* Severe thrombocytopenia (\\\u003C 50× 109\u002FL)","28 Weeks",{"count":365,"type":21},26,[341],"Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even death if it remains open and large. When closure of PDA is needed, doctors make every attempt to do it as soon as possible. Ibuprofen is the best drug to close the PDA, but it only works for 50% of small newborns. The investigators have shown before that small newborns handle ibuprofen differently and the amount of active ibuprofen that reaches their blood can be very unpredictable. Studies have shown if enough ibuprofen reaches the body, it can close the PDA. Therefore the investigators designed this study to see whether it is possible to give each newborn the right amount of ibuprofen that their body needs to close the PDA. The investigators will compare two ways to give ibuprofen in a small number of newborns: 1 - standard amount of ibuprofen to everyone, which is the usual care or 2 - ibuprofen doses that will be changed based on how much active ibuprofen has reached the body and how well the newborn's PDA is closing. The investigators will then compare the number of PDAs closed in each group and closely monitor any possible challenges for this new practice. By doing this project, the goals can be summarized as below:\n\nA. Primary goal: To determine if it is feasible to successfully run a larger study in the future.\n\nB. Secondary goals\n\n1. To assess how well and how safely the personalized (MIPD) method works, using a tool called WAPPS-PDA to guide dosing.\n2. To compare the effectiveness and safety of the personalized method with standard ibuprofen dosing.\n3. To identify drug levels in the blood (Cmin, AUC0-24, AUC0-72) that are associated with complete, partial, or no response to treatment.",[369,370],"Patent Ductus Arteriosus","Preterm",[361,372,373,374],"PDA","Precision Dosing","Ibuprofen","2025-08-19",{"date":377,"type":36},"2025-08-27",{"date":379,"type":36},"2024-07-04",{"date":381,"type":21},"2027-07",{"name":42,"class":43},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":110,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100602068","phase-3-evaluating-a-shorter-rifampicin-based-treatment-for-people-with-less-severe-tuberculosis-disease-100602068","NCT07118696","Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease","Shortening TB Treatment With Optimised Rifampicin-Based Therapy and Disease Stratification: A Pragmatic Phase 3 Double-Blind Placebo-Controlled Randomised Trial (RIFAstrat)","RIFAstrat","Inclusion Criteria:\n\n1. Aged 12 years and over\n2. Clinical and\u002For radiological evidence of pulmonary TB\n3. At least one sputum specimen positive for M. tuberculosis by Xpert MTB\u002FRIF or Ultra within 30 days of screening confirming rifampicin-sensitive TB\n4. Have limited TB disease defined as having a cycle threshold on sputum Xpert MTB\u002FRIF or Ultra corresponding to 'medium' or below for bacterial burden at screening (where results from more than one test are available at screening, eligibility will be determined by the highest grade)\n5. Documentation of HIV status from a validated test performed within 30 days of screening or known to be HIV-positive\n6. Well enough to be treated as an outpatient\n\nExclusion Criteria:\n\n1. Received more than 7 days treatment for index TB episode\n2. Previous treatment for active TB disease in past 12 months\n3. M. tuberculosis with known resistance to rifampicin or isoniazid\n4. Weight \\\u003C 30 kg at screening\n5. Sick with one or more WHO 'danger signs' at screening (respiratory rate \\> 30 breaths per minute, temperature \\> 39 ˚C, heart rate \\> 120 bpm, inability to walk unaided)\n6. Suspected or confirmed extra-pulmonary TB involving the central nervous system, bones, joints, abdomen, and\u002For pericardium (coexistent pleural or lymph node TB are not exclusions)\n7. For participants living with HIV:\n\n   * Urinary lipoarabinomannan test positive at screening\n   * Requires protease inhibitor-based antiretroviral therapy, and\u002For long acting antiretrovirals cabotegravir\u002Frilpivirine\n8. For participants of child-bearing potential: currently pregnant or not currently pregnant but unwilling to practice an effective method of contraception during study drug treatment\n9. Clinical evidence of acute hepatitis or advanced chronic liver disease (e.g. jaundice, signs of portal hypertension)\n10. Known end stage renal failure\n11. Active malignancy not in remission or had systemic chemotherapy within 2 years (except for non-melanomatous skin cancer)\n12. Contraindication to study medications because of known allergy or intolerance or unavoidable drug-drug interaction\n13. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest\n14. Inability to attend follow up visits",{"count":392,"type":21},1000,[147],"RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.",[396],"Pulmonary TB",[398,399],"Rifampicin","Treatment Shortening","2025-08-07",{"date":402,"type":36},"2025-08-12",{"date":404,"type":21},"2026-02-01",{"date":406,"type":21},"2030-01-31",{"name":42,"class":43},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":416,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":44},"100585924","phase-4-investigation-of-glp1-receptor-agonists-in-men-with-prostate-cancer-taking-androgen-deprivation-therapy-100585924","NCT06908694","Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy","GLP1-Receptor Agonists in Men With Prostate Cancer: Control of Cardiovascular Risk Factors and Prostate Biomarkers","GAINPCCONTROL","Inclusion Criteria:\n\n* Have a physician diagnosis of PC\n* Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)\n* Elevated BMI\n\n  1. ≥30kg\u002Fm2 or\n  2. ≥27kg\u002Fm2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Taking a GLP-1 RA\n* \\\u003C18 years of age\n* History of pancreatitis\n* Personal or family history of medullary cancer of the thyroid\n* Multiple endocrine neoplasia type 2","MALE",{"count":113,"type":21},[293],"GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.",[421],"Prostate Cancer",[423,424],"Androgen Deprivation Therapy","GLP-1 Receptor Agonists","2025-07-25",{"date":427,"type":36},"2025-07-29",{"date":429,"type":36},"2025-07-02",{"date":431,"type":21},"2026-07-31",{"name":42,"class":43},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":443,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":44},"100595052","phase-3-radiation-therapy-followed-by-durvalumab-medi4736-and-tremelimumab-and-surgery-versus-radiation-therapy-followed-by-surgery-for-resectable-hepatocellular-carcinoma-100595052","NCT07027436","Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.","Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. A Randomized Window of Opportunity Trial (DARTS)","DARTS","Inclusion Criteria:\n\n* Radiologically or biopsy proven solitary HCC without biliary invasion or metastases, Liver Imaging Reporting and Data Systems (LI- RADS) 4 or 5 only. Participants with satellite tumour nodules are eligible. Satellitosis or a satellite nodule is defined as a tumour (LI-RADS 4 or 5 only) less than or equal to 2 cm and located less than or equal to 2 cm from the main tumour.\n\nTumour less than 12 cm in maximum size on CT or MRI.\n\nPlanned surgical resection of HCC with a life expectancy of at least 12 weeks\n\nAge \\>18 years at time of study entry.\n\nChild-Pugh Class A within 14 days prior to study enrollment\n\nEastern Cooperative Oncology Group (ECOG) of 0 or 1 (see Appendix 3)\n\nBody weight \\>30 kg at time of study enrollment\n\nAdequate normal organ and marrow function as defined below:\n\nHaemoglobin ≥9.0 g\u002FdL\n\nAbsolute neutrophil count (ANC ≥1.0 × 109 \u002FL)\n\nPlatelet count ≥75 × 109\u002FL\n\nSerum bilirubin ≤1.5 x institutional upper limit of normal (ULN).\n\nAST (SGOT)\u002FALT (SGPT) ≤2.5 x institutional upper limit of normal\n\nMeasured creatinine clearance (CL) \\>40 mL\u002Fmin or Calculated creatinine clearance CL\\>40 mL\u002Fmin by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:\n\nMales:\n\nCreatinine CL (mL\u002Fmin) = Weight (kg) x (140 - Age)72 x serum creatinine (mg\u002FdL)\n\nFemales:\n\nCreatinine CL (mL\u002Fmin) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg\u002FdL)\n\nPatient is capable and willing to provide signed informed consent.\n\nExclusion Criteria:\n\n* Previous therapy for HCC, including systemic therapy, surgery, radiation therapy, ablation or embolization.\n\nParticipation in another clinical study with an investigational product during the last 4 weeks or concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n\nAny concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n\nPrevious radiation therapy or surgery within 4 weeks of the randomization.\n\nPrevious allogenic organ transplantation\n\nPrevious anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy\n\nPrevious receipt of durvalumab and \u002F or tremelimumab or allergy to it\n\nAny unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy except for alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\nPatients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n\nPatients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.\n\nActive or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\\]). The following are exceptions to this criterion:\n\nPatients with vitiligo or alopecia\n\nPatients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n\nAny chronic skin condition that does not require systemic therapy\n\nPatients without active disease in the last 5 years may be included but only after consultation with the study physician\n\nPatients with celiac disease controlled by diet alone\n\nHistory of active primary immunodeficiency\n\nConditions that would preclude administration of durvalumab and \u002F or tremelimumab\n\nUncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n\nKnown active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Patients with a past or resolved HBV infection (defined as the presence of antiHBc and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n\nb.1. Patients co-infected with HBV and HCV or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and\u002For anti HBcAb with detectable HBV DNA); and\n\nb.2. HCV positive (presence of anti-HCV antibodies); or\n\nb.3. HDV positive (presence of anti-HDV antibodies)\n\nb.4. Patients with HBV infection, characterized by positive HBsAg and\u002For anti-HBcAb with undetectable HBV DNA (\\\u003C 10 IU\u002Fml or under the limit of detection per local lab standard) do not require antiviral therapy prior to enrollment. These patients will be tested once for HBV DNA levels; if HBV DNA is detected (≥ 10 IU\u002Fml or above the limit of detection per local lab standard), antiviral therapy must be initiated, continued for the study duration and for 6 months after the last dose of IP.\n\nKnown to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) which is not well controlled or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n\nc.1. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of \\>200 no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medications.\n\nHistory of another primary malignancy, except for\n\nMalignancy treated with curative intent and with no known active disease ≥2 years before randomization and of low potential risk for recurrence\n\nAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n\nAdequately treated carcinoma in situ without evidence of disease\n\nCurrent or prior use of immunosuppressive medication within 14 days before enrollment. The following are exceptions to this criterion:\n\nIntranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n\nSystemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n\nSteroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n\nReceipt of live attenuated vaccine within 30 days prior to enrollment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90 days after the last dose of IP.\n\nFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab and tremelimumab combination therapy.",{"count":442,"type":21},30,[147],"The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC).\n\nThe study hypothesizes is that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. The study hypothesizes that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. A biological response, or change in the tumor microenvironment (TME), is defined by reduced infiltration of intra-tumoral regulatory T cells (Tregs), a decrease in tumour-associated macrophages (TAMs) of the M2 phenotype, and an increase in immune cells such as effector CD8+ T-cells. An increased rate of biological response is therefore expected in participants receiving the combination of Durvalumab, Tremelimumab, and stereotactic body radiation therapy (SBRT), compared to those receiving SBRT alone. Additionally, biological response is hypothesized to correlate with pathological response.\n\nThe study has been conducted within a WOO window of opportunity randomized clinical trial in order to obtain data in the quickest and safest manner. Patients undergoing surgery are very healthy by definition and will be able to tolerate treatment without any major complications, leading to adequate tissue samples before and after treatment.",[446],"Hepatocellular Carcinoma (HCC)",[448,449],"Durvalumab\u002Ftremelimumab, SBRT, radiation, HCC","WOO, Window of Opportunity","2025-06-16",{"date":452,"type":36},"2025-06-18",{"date":454,"type":21},"2025-07-07",{"date":456,"type":21},"2028-10-10",{"name":42,"class":43},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":465,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":44},"100506399","phase-3-colchicine-and-thiamine-in-heart-failure-due-to-ischemic-heart-disease-100506399","NCT05873881","COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease","COLT-HF","Inclusion Criteria:\n\n1. Age \\>\u002F= 45 years\n2. Documented ischemic HF as the etiology of HF, which includes:\n\n   1. a prior history of CAD (defined as a history of myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, or non-invasive or invasive cardiac testing consistent with a diagnosis of CAD), and\n   2. determination of CAD to be the cause primary cause of HF based on local investigator assessment\n3. New York Heart Association (NYHA) class II-IV symptoms\n4. Documented LVEF \\\u003C\u002F= 45% within 1 year prior to enrollment\n5. Optimization of HF treatment based on local practice.\n6. Ambulatory HF patients or stable hospitalized patients with HF will both be eligible for enrollment in the trial. For hospitalized patients, enrollment will require i) evidence of clinical stability from HF defined as no use of an inotropic agent or intravenous diuretic agent in the prior 24, and ii) expected discharge from hospital in the next 72 hours.\n\nExclusion Criteria:\n\n1. Female who is pregnant, breast-feeding, or of childbearing potential and not using an effective form of birth control\\*\n2. Regular or required use colchicine or thiamine for other clinical indications.\\*\\*\n3. History of allergic reaction to colchicine or to thiamine; or current or planned use of cyclosporine, verapamil, diltiazem, azole antifungal, macrolide antibiotic (except azithromycin), or HIV protease inhibitor\n4. Use of a ventricular assist device or prior heart transplant\n5. Coronary revascularization (coronary artery bypass graft surgery or percutaneous coronary intervention) within the 4 weeks prior to enrollment, or planned within the next 4 weeks.\n6. Severe valvular disease\n7. Chronic and severe renal dysfunction defined as eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2 based on local laboratory measurement done within 6 months prior to run-in\\*\\*\\*\n8. History of liver cirrhosis\n9. Active malignancy (excluding basal cell or treated squamous cell carcinoma of the skin) requiring treatment and with a life-expectancy of \\\u003C 2 years.\n10. Concurrent use of other experimental pharmacologic agents -","45 Years",{"count":467,"type":21},2500,[147],"The goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and ii) thiamine in heart failure (HF) secondary to ischemic heart disease. The main questions it aims to answer are:\n\n* Does colchicine reduce the risk of cardiovascular (CV) death, a HF event, or an ischemic CV event\n* Does thiamine reduce the risk of cardiovascular (CV) death, or a HF event\n\nParticipants will undergo the following procedures:\n\n* Run-in: All participants will receive colchicine 0.5 mg daily to assess drug tolerance over a 3-4 week period.\n* Randomization: If colchicine is tolerated during run-in, eligible participants will be randomized in a 2x2 factorial design to receive i) colchicine 0.5mg daily or placebo, and ii) thiamine 300mg daily or no thiamine.\n* Follow-up: Clinical outcomes, side effects, adverse events, and drug adherence will be captured during follow-up",[471],"Heart Failure",{"date":473,"type":36},"2025-06-19",{"date":475,"type":36},"2024-01-29",{"date":163,"type":21},{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":485,"enrollmentInfo":486,"targetDuration":487,"studyType":196,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":44},"100590743","health-literacy-in-geriatric-patients-100590743","NCT06971393","Health Literacy in Geriatric Patients","A Comparison of Health Literacy Estimates Among Patients, Caregivers and a Geriatric Team","Inclusion Criteria:\n\n* Patients (both new and follow up) attending St. Peter's Hospital Geriatric Clinic\n* Willingness to participate in the study (caregiver can rate HL for patient if patient unable to)\n* Consenting to study (by patient or caregiver)\n\nExclusion Criteria:\n\n* Behavior (e.g. behavioral and psychological symptoms of dementia) which may be aggravated by additional questions\n* Acute illness preventing participation\n* Terminal illness that would prevent 6-month telephone follow up\n* Previous participation in this study","110 Years",{"count":145,"type":21},"6 Months","Health Literacy is one's ability to understand health information well enough to make informed decisions about their health. Limited health literacy makes it hard for people to understand complex health issues and follow health care recommendations. Limited health literacy is associated with adverse health outcomes such as higher mortality, increased risk of emergency department visits and hospital admissions leading to higher medical costs. Although there are tools to assess health literacy, they are not widely used, so many healthcare providers do not measure their patients' health literacy levels adequately. Health care workers tend to overestimate their patients' health literacy. This is especially important for older adults who often have memory problems and multiple illnesses. This study will evaluate how doctors and team members in a geriatric clinic estimate their patient's health literacy and determine if this matches with the patients' health literacy as measured by a simple validated questionnaire. The investigators will also look at how a patient's relative or caregiver estimates their health literacy using a similar short questionnaire. The research team plans to follow up with a telephone call in 6 months, to see which health concerns if any have occurred since the clinic visit.",[490],"Health Literacy",[490,492,493,494,495,496,497,498,499],"Geriatric health literacy assessment","Health literacy in tertiary care settings","Correlation of health literacy and health outcomes","BRIEF health literacy questionnaire","Visual Analogue Scale quality of life measure","Emergency room visits and hospitalization tracking in geriatric population","Patient-provider health literacy perception agreement","Patient, caregiver, and geriatric team health literacy alignment","2025-05-14",{"date":502,"type":36},"2025-05-18",{"date":504,"type":36},"2025-02-26",{"date":506,"type":21},"2025-12-31",{"name":42,"class":43},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":515,"maxAge":111,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":524,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":541,"locationsCount":44},"100580340","phase-2-a-trial-of-actazin-versus-peg-3350-for-maintenance-therapy-in-children-with-constipation-100580340","NCT06836024","A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation","Actazin (Kiwifruit Extract) Versus Polyethylene Glycol 3350 for Maintenance Therapy in Children With Constipation: a Feasibility Randomized Control Trial","Inclusion Criteria:\n\n1. Age 4 to 17 years, inclusive; minimum age of 4 years to ensure toileting skills have been acquired and ability to chew and swallow tablets safely.\n2. Fulfill Rome IV diagnostic criteria for FC;60 Must include ≥2 of the following occurring at least once per week for a minimum of 1 month: (i) ≤2 SBMs\u002F week; (ii) ≥1 episode of fecal incontinence\u002Fweek; (iii) retentive posturing; (iv) painful or hard bowel movements; (v) presence of a large fecal mass in the rectum (rectal, abdominal or radiographic exam) and (vi) history of large-diameter stools that can obstruct the toilet.\n3. Participant and their caregivers agree to exclusively use the laxatives provided as part of the trial for a 4-week period, and refrain from using any additional PEG 3350 or kiwifruit\u002Fkiwifruit extracts outside of the trial products.\n\nExclusion Criteria:\n\n1. Organic causes of constipation (e.g., celiac disease, Hirschsprung's disease, spina bifida, anorectal malformations)\n2. Prior enrollment in trial\n3. Not toilet trained; significantly different FC phenotype than toilet trained children\n4. Any known hypersensitivity to kiwifruit, latex, Actazin or PEG 3350\n5. Chronic health conditions (e.g., urolithiasis, ureteropelvic junction obstruction, sickle cell, cerebral palsy, hepatic, hematopoietic, renal, endocrine, or metabolic diseases) that could potentially confound the results of the study\n6. Prior abdominal surgery involving the luminal GI tract, except hernia repairs\n7. Concomitant use of drugs that are known to affect GI motility (e.g., opioids, domperidone, linaclotide)\n8. Prior neuropsychiatric or pervasive developmental disorders such as severe non-verbal ASD, major psychiatric disorders (bipolar disorder, schizophrenia, major depression)\n9. Refractory or severe FC that failed to respond to PEG 3350 and\u002For require combination of several laxative therapies, manual disimpaction, use of any nerve stimulation or antegrade enemas through a cecostomy or an appendicostomy\n10. Absence of a parent\u002Fguardian for children who are not mature minors\n11. Inability to obtain consent due to a language barrier and the absence of language translator in person or by a phone translation service available in the ED","4 Years",{"count":517,"type":21},60,[341,147],"The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation.\n\nThe main questions it aims to answer are:\n\n1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC?\n2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period?\n\nResearchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC.\n\nParticipants will:\n\nUndergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups:\n\n1. Actazin chewable tablets (titrate to effect: 600-2400 mg\u002Fday) + placebo PEG 3350\n2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events.\n\nAdditionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes.\n\nOutcomes:\n\nPrimary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate.\n\nSecondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability.\n\nThis study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumedi™ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).",[521,522,523],"Constipation - Functional","Constipation","Constipation Aggravated",[525,526,527,528,529,530,531,532,533,534],"Functional Constipation","Pediatric Constipation","Actazin","Kiwifruit Extract","Polyethylene Glycol 3350","Laxative Therapy","Randomized Controlled Trial","Feasibility Study","Non-Pharmacologic Treatment","Rome IV Criteria","2025-03-14",{"date":537,"type":36},"2025-03-19",{"date":539,"type":21},"2025-06-01",{"date":234,"type":21},{"name":42,"class":43},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":165},"100531759","phase-1-inflammation-reduction-to-prevent-cardiovascular-injury-in-renal-disease-repair-100531759","NCT06203977","Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)","Inclusion Criteria:\n\n1. One of either:\n\n   1.2 Estimated GFR using CKD-EPI 2021 equation of ≤30 ml\u002Fmin\u002F1.73m2 on at least two occasions separated by at least 2 months and do not yet require dialysis and are not expected by their treating nephrologist to require dialysis in the next 6 months (REPAIR CKD cohort), or 1.3 receiving chronic maintenance dialysis 2 or more times per week for the previous 90 days (REPAIR Dialysis cohort);\n2. Age ≥18 years\n3. Provide informed consent to participate.\n\nExclusion Criteria:\n\n1. Currently treated with and cannot withdraw colchicine due to medical necessity; or\n2. Known allergy\u002Fsensitivity to colchicine; or\n3. Prior self-reported intolerance to colchicine at a dose of 0.6 mg daily or lower; or\n4. Currently pregnant or planning to become pregnant or breastfeed during the study; or\n5. Of childbearing potential AND do not have a negative pregnancy test OR do not agree to use two forms of contraception for the duration of the study; or\n6. Anticipated living donor renal transplant within the next 6 months; or\n7. Using a strong inhibitor of p-glycoprotein or strong inhibitor of CYP3A4 in the last 14 days; or\n8. B12 deficiency not managed with intramuscular supplementation; or\n9. Uncontrolled chronic diarrhea; or\n10. Cirrhosis, or chronic active hepatitis; or\n11. Pre-existent neuromuscular disease or persistent serum CK level \\> 3 times the upper limit of normal as measured within the past 60 days and determined to be non-transient through repeat testing; or\n12. Patient with any of the following within the past 60 days:\n\n    * white blood cell count \\\u003C 3.0 X 109\u002FL; or\n    * platelet count \\\u003C110 X 109\u002FL; or\n    * ALT or AST \\> 3 times the upper limit of normal (ULN); or\n    * total bilirubin \\> 2 times ULN and not due to Gilbert syndrome.\n13. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.",{"count":549,"type":21},200,[551],"PHASE1","Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.",[150,554],"Renal Failure",[556,557,558],"Tolerance","Colchicine Resistance","Hematologic markers","2025-03-10",{"date":561,"type":36},"2025-03-12",{"date":563,"type":36},"2024-11-15",{"date":565,"type":21},"2026-05-31",{"name":42,"class":43},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":269,"sex":17,"minAge":575,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":44},"100581013","score-active-trial-100581013","NCT06844786","SCORE! ACTIVE Trial","SCORE! ACTIVE: Advancing Codesigned Health Promotion and Physical Activity Interventions to Improve Self-Efficacy and Health: A Stepped Wedge Cluster Randomized Trial","ACTIVE","Inclusion Criteria:\n\n* Newcomer families (those who have been in Canada for 10 years or less) with at least 1 child aged 5 up to 11 (11.99 years) living in a Hamilton, Ontario.\n* At least one parent\u002Fguardian born outside of Canada and residing in Canada ≤ 10 years.\n* Families must be living in one of the designated neighbourhood clusters\n\nExclusion Criteria:\n\n* Children participating in organized physical activity programs for 3 or more times per week\n* Families with involvement with child protection services and\u002For foster care","5 Years","11 Years",{"count":578,"type":21},1400,[24],"Hamilton is a city with a growing newcomer population. Families who are new to Canada do not always have the same resources to access healthy active living (HAL) activities as compared to Canadian-born families. The SCORE! ACTIVE trial will recruit newcomer families with young children in Hamilton and help provide them with access to HAL activities. Through this, the investigators want to see if newcomer children's perspectives of physical activity will change over time. They will also see if increasing newcomer children's access to these resources will promote an increase in HAL behaviours.",[582,583],"Chronic Disease","Childhood Obesity","2025-02-19",{"date":586,"type":36},"2025-02-25",{"date":588,"type":21},"2025-03-01",{"date":590,"type":21},"2028-08-31",{"name":42,"class":43},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":22,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":4},"100508226","phase-3-levetiracetam-prophylaxis-in-brain-tumor-resection-pilot-100508226","NCT05897658","Levetiracetam Prophylaxis in Brain Tumor Resection Pilot","Pilot Study: Levetiracetam Prophylaxis Randomized Controlled Trial in Brain Tumor Resection","LeviTaTe Pilot","Inclusion Criteria:\n\n* Adult age 18 years or older\n* Undergoing craniotomy for a brain tumor\n* Intra-axial tumor location\n* Supratentorial tumor location\n\nExclusion Criteria:\n\n* Documented seizure history or epilepsy diagnosis\n* Currently taking an antiepileptic medication\n* Unable to take levetiracetam (e.g. allergy, inability to swallow)\n* Inability to obtain consent from participant or substitute decision maker prior to surgery\n* Renal impairment with eGFR less than 50\n* Pregnancy",{"count":220,"type":21},[147],"This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.",[604,605],"Seizures","Brain Tumor","2024-10-21",{"date":608,"type":36},"2024-10-23",{"date":610,"type":21},"2025-03",{"date":612,"type":21},"2026-03",{"name":42,"class":43},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":44},"100319474","to-brace-or-not-to-brace-for-single-level-lumbar-fusion-pilot-100319474","NCT03439228","To Brace or Not to Brace for Single Level Lumbar Fusion Pilot","To Brace or Not to Brace for Single Level Lumbar Fusion: a Pilot Prospective Randomized Controlled Trial","BRACE Pilot","Inclusion Criteria:\n\n* Single-level lumbar instrumented postero-lateral fusion from L2-L5\n* Life expectancy greater than 2 years\n\nExclusion Criteria:\n\n* Previous lumbar surgery\n* Spine tumour\u002Fcancer\n* Documented osteoporosis\n* High grade (3 or 4) spondylolisthesis","80 Years",{"count":624,"type":21},50,[24],"The use of a lumbar brace following single-level lumbar fusion for degenerative spondylosis (non-traumatic) is variable between surgeons. Some surgeons prefer to prescribe a brace and others do not. There is a lack of guidelines and evidence to support either treatment option. The purpose of this study is to assess feasibility and collect preliminary data to conduct a larger, definitive trial to provide evidence as to whether prescribing a brace or not results in better or equal outcomes. Imaging by CT scan, one year after surgery, will be used to analyze bone fusion (healing), and functional and pain scores from patients during their recovery will be compared to identify differences between patients who wore a brace and those who did not.",[628,629],"Lumbar Spondylosis","Fusion of Spine",{"date":608,"type":36},{"date":632,"type":36},"2018-07-16",{"date":634,"type":21},"2025-12",{"name":42,"class":43},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":269,"sex":416,"minAge":644,"maxAge":645,"enrollmentInfo":646,"targetDuration":4,"studyType":22,"phases":648,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":44},"100523157","phase-2-supplementation-for-male-subfertility-100523157","NCT06091969","Supplementation for Male Subfertility","Nutraceutical Supplementation for Male Subfertility","FertEnhancer","Inclusion Criteria:\n\n* Males between the ages of 25-50 years diagnosed with subfertility through Ontario Networks of Experts in Fertility (ONE Fertility, Burlington, ON).\n* For diagnosis of male subfertility, the 2010 and 2021 World Health Organization criteria will be used for sperm count, motility, morphology and vitality.\n* Overweight and obese males according to body mass index (BMI) between the ages of 25-50 years.\n\nExclusion Criteria:\n\n* Smoking,\n* history and drug alcohol abuse,\n* BMI \\> 30 kg\u002Fm2,\n* genital disease (cryptorchidism, current genital inflammation, or varicocele),\n* genital trauma or surgery to the male reproductive system,\n* known Y chromosome microdeletions or karyotype abnormalities (if known prior),\n* hepatobiliary disease,\n* significant renal insufficiency,\n* occupational exposures to reproductive toxins,\n* endocrine abnormality,\n* recent or current sexually transmitted infection,\n* use of cytotoxic drugs,\n* use of immunosuppressants,\n* use of anticonvulsants,\n* use of androgens or antiandrogens,\n* history of central nervous system injury,\n* neurological or psychiatric disease to potentially compromise study data collection,\n* treatment of erectile dysfunction with any drugs during the past 4 weeks,\n* history of cancer chemotherapy,\n* current supplementation with ingredients being tested unless 1-month washout period","25 Years","50 Years",{"count":647,"type":21},64,[341],"Old age, obesity, physical inactivity, environmental factors and genetics may contribute negatively to fertility in both males and females. In males, specifically, certain supplements, such as single antioxidants and trace minerals, have previously been shown to improve sperm function marginally. One hypothesis is that sperm function can be improved even further by combining several different types of supplements (e.g., amino acids, energy carriers, vitamins, antioxidants, and trace minerals) to target several age-related cell pathways, for example, oxidative stress, mitochondrial dysfunction, inflammation and cell energetics. This 3-month placebo-controlled, randomized clinical trial, aims to test the effects of a novel multi-ingredient supplement (Fertility Enhancer) that targets several age-related cell pathways on sperm function in overweight or obese and subfertile males.",[651],"Male Infertility",[653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668],"Sub-fertility","Infertility","Antioxidants","Supplements","Creatine","Arginine","Vitamins","Aging","Oxidative stress","Inflammation","DNA","Mitochondria","Fragmentation","ATP","Weight loss","Obesity","2024-10-08",{"date":671,"type":36},"2024-10-10",{"date":673,"type":21},"2025-01-01",{"date":675,"type":21},"2026-02-02",{"name":42,"class":43},""]